Last reviewed · How we verify
AAV2-GDNF
AAV2-mediated delivery of glial cell line-derived neurotrophic factor
AAV2-mediated delivery of glial cell line-derived neurotrophic factor Used for Amyotrophic lateral sclerosis (ALS).
At a glance
| Generic name | AAV2-GDNF |
|---|---|
| Sponsor | Brain Neurotherapy Bio, Inc. |
| Drug class | Gene therapy |
| Target | GDNF |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | Phase 1 |
Mechanism of action
AAV2-GDNF uses adeno-associated virus 2 to deliver glial cell line-derived neurotrophic factor to the brain, promoting neuronal survival and growth.
Approved indications
- Amyotrophic lateral sclerosis (ALS)
Common side effects
Key clinical trials
- AAV2-GDNF for Advanced Parkinson s Disease (PHASE1)
- GDNF Gene Therapy for Multiple System Atrophy (PHASE1)
- A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) (PHASE2)
- GDNF Gene Therapy for Parkinson's Disease (PHASE1)
- Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AAV2-GDNF CI brief — competitive landscape report
- AAV2-GDNF updates RSS · CI watch RSS
- Brain Neurotherapy Bio, Inc. portfolio CI